Biophytis S.A. Cash Flow Conversion Efficiency
Biophytis S.A. cash flow conversion efficiency. Based on the latest financial reports, Biophytis S.A. (BPTSY) has a cash flow conversion efficiency ratio of 0.000x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.98K) by net assets ($-6.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biophytis S.A. (2013–2023)
Cash flow conversion efficiency of Biophytis S.A. from 2013 to 2023. This chart illustrates how Biophytis S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View BPTSY stock price for real-time trading data and today's change.
Biophytis S.A. Cash Flow Conversion Ratio Explained
Biophytis S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biophytis S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biophytis S.A. ranked by their cash flow conversion efficiency. Also see Biophytis S.A. (BPTSY) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DTCOM - Direct to Company S.A
SA:DTCY3
|
-3.060x |
|
Dimet (Siam) Public Company Limited
BK:DIMET
|
-0.055x |
|
Bold Ventures Inc
V:BOL
|
-0.132x |
|
Bri-Chem Corp.
TO:BRY
|
0.008x |
|
Capitan Investment Ltd
V:CAI
|
0.042x |
|
Henderson International Income Trust PLC
LSE:HINT
|
0.024x |
|
Pantera Lithium Ltd
AU:PFE
|
-0.028x |
|
Inhalerx Ltd
AU:IRX
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Biophytis S.A. (2013–2023)
The table below shows the annual cash flow conversion efficiency of Biophytis S.A. from 2013 to 2023. Review Biophytis S.A. free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-3.89 Million | $-12.87 Million | 3.310x | -66.69% |
| 2022-12-31 | $-1.91 Million | $-18.99 Million | 9.936x | +338.23% |
| 2021-12-31 | $5.71 Million | $-23.80 Million | -4.171x | -188.88% |
| 2020-12-31 | $6.83 Million | $-9.86 Million | -1.444x | -171.15% |
| 2019-12-31 | $-7.53 Million | $-15.27 Million | 2.029x | +217.92% |
| 2018-12-31 | $7.01 Million | $-12.06 Million | -1.721x | -317.79% |
| 2017-12-31 | $21.19 Million | $-8.73 Million | -0.412x | +71.94% |
| 2016-12-31 | $4.52 Million | $-6.63 Million | -1.468x | -433.55% |
| 2015-12-31 | $11.67 Million | $-3.21 Million | -0.275x | -147.13% |
| 2014-12-31 | $-1.13 Million | $-658.89K | 0.584x | -70.26% |
| 2013-12-31 | $-409.32K | $-803.29K | 1.962x | -- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, … Read more